{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T20:07:13Z","timestamp":1648843633263},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s11938-007-0056-5","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T13:59:28Z","timestamp":1205848768000},"page":"47-56","source":"Crossref","is-referenced-by-count":5,"title":["Heartburn refractory to proton-pump inhibitors"],"prefix":"10.1007","volume":"10","author":[{"given":"Apurva","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,19]]},"reference":[{"key":"56_CR1","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0016-5085(97)70025-8","volume":"112","author":"G.R. Locke 3rd","year":"1997","unstructured":"Locke GR 3rd, Talley NJ, Fett SL, et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997, 112:1448\u20131456.","journal-title":"Gastroenterology"},{"key":"56_CR2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.gastro.2004.08.014","volume":"128","author":"W.J. Barlow","year":"2005","unstructured":"Barlow WJ, Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005, 128:771\u2013778.","journal-title":"Gastroenterology"},{"key":"56_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","volume":"22","author":"R. Fass","year":"2005","unstructured":"Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2014where next? Aliment Pharmacol Ther 2005, 22:79\u201394.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","volume":"97","author":"D.O. Castell","year":"2002","unstructured":"Castell DO, Kahrilas PJ, Richter JE, et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575\u2013583.","journal-title":"Am J Gastroenterol"},{"key":"56_CR5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","volume":"2","author":"B.B. Dean","year":"2004","unstructured":"Dean BB, Gano AD, Knight K, et al.: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656\u2013664.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"56_CR6","volume-title":"Gallup study of consumers\u2019 use of stomach relief products","author":"The Gallup Organization","year":"2000","unstructured":"The Gallup Organization: Gallup study of consumers\u2019 use of stomach relief products. Princeton, NJ: The Gallup Organization; 2000."},{"key":"56_CR7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1365-2036.2003.01645.x","volume":"17","author":"L.J. Egan","year":"2003","unstructured":"Egan LJ, Myhre GM, Mays DC, et al.: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003, 17:1521\u20131528.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","volume":"93","author":"P.L. Peghini","year":"1998","unstructured":"Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998, 93:763\u2013767.","journal-title":"Am J Gastroenterol"},{"key":"56_CR9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1046\/j.1365-2036.2002.t01-1-01281.x","volume":"16","author":"U.C. Nzeako","year":"2002","unstructured":"Nzeako UC, Murray JA: An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002, 16:1309\u20131316.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2005.08.060","volume":"130","author":"J.P. Galmiche","year":"2006","unstructured":"Galmiche JP, Clouse RE, Balint A, et al.: Functional esophageal disorders. Gastroenterology 2006, 130:1459\u20131465.","journal-title":"Gastroenterology"},{"key":"56_CR11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00042737-200602000-00015","volume":"18","author":"S.N. Sgouros","year":"2006","unstructured":"Sgouros SN, Bergele C, Mantides A: Eosinophilic esophagitis in adults: a systematic review. Eur J Gastroenterol Hepatol 2006, 18:211\u2013217.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"56_CR12","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1053\/gast.1996.1101982","volume":"110","author":"P.J. Kahrilas","year":"1996","unstructured":"Kahrilas PJ, Quigley EM: Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996, 110:1982\u20131996.","journal-title":"Gastroenterology"},{"key":"56_CR13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1572-0241.2004.04171.x","volume":"99","author":"J. Tack","year":"2004","unstructured":"Tack J, Koek G, Demedts I, et al.: Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett\u2019s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004, 99:981\u2013988.","journal-title":"Am J Gastroenterol"},{"key":"56_CR14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s10620-005-2960-7","volume":"50","author":"J.M. Bautista","year":"2005","unstructured":"Bautista JM, Wong WM, Pulliam G, et al.: The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005, 50:1909\u20131915.","journal-title":"Dig Dis Sci"},{"key":"56_CR15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1572-0241.2005.41210.x","volume":"100","author":"S. Charbel","year":"2005","unstructured":"Charbel S, Khandwala F, Vaezi MF: The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005, 100:283\u2013289.","journal-title":"Am J Gastroenterol"},{"key":"56_CR16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1136\/gut.2005.087668","volume":"55","author":"I. Mainie","year":"2006","unstructured":"Mainie I, Tutuian R, Shay S, et al.: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006, 55:1398\u20131402.","journal-title":"Gut"},{"key":"56_CR17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1046\/j.1365-2036.2000.00882.x","volume":"14","author":"R. Fass","year":"2000","unstructured":"Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastrooesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14:1595\u20131603.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-3565(05)00860-8","volume":"4","author":"R. Fass","year":"2006","unstructured":"Fass R, Sontag SJ, Traxler B, Sostek M: Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006, 4:50\u201356.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"56_CR19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/gast.2002.31876","volume":"122","author":"W.K. Fackler","year":"2002","unstructured":"Fackler WK, Ours TM, Vaezi MF, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002, 122:625\u2013632.","journal-title":"Gastroenterology"},{"key":"56_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1572-0241.2003.07304.x","volume":"98","author":"T.M. Ours","year":"2003","unstructured":"Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003, 98:545\u2013550.","journal-title":"Am J Gastroenterol"},{"key":"56_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0016-5085(00)70408-2","volume":"118","author":"I. Lidums","year":"2000","unstructured":"Lidums I, Lehmann A, Checklin H, et al.: Control of transient lower sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology 2000, 118:7\u201313.","journal-title":"Gastroenterology"},{"key":"56_CR22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/gut.50.1.19","volume":"50","author":"Q. Zhang","year":"2002","unstructured":"Zhang Q, Lehmann A, Rigda R, et al.: Control of transient lower oesophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19\u201324.","journal-title":"Gut"},{"key":"56_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2036.2003.01394.x","volume":"17","author":"M.F. Vela","year":"2003","unstructured":"Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid post-prandial gastrooesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17:243\u2013251.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR24","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1136\/gut.52.10.1397","volume":"52","author":"G.H. Koek","year":"2003","unstructured":"Koek GH, Sifrim D, Lerut T, et al.: Effect of the GABA (B) agonist baclofen in patients with symptoms of duodenogastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52:1397\u20131402.","journal-title":"Gut"},{"key":"56_CR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2982.2005.00715.x","volume":"17","author":"L. Degen","year":"2005","unstructured":"Degen L, Petrig C, Studer D, et al.: Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005, 17:821\u2013826.","journal-title":"Neurogastroenterol Motil"},{"key":"56_CR26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2036.2006.02968.x","volume":"24","author":"R. Tutuian","year":"2006","unstructured":"Tutuian R, Mainie I, Allan R, et al.: Effects of a 5-HT (4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 2006, 24:155\u2013162.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2000.00854.x","volume":"14","author":"P.J. Kahrilas","year":"2000","unstructured":"Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14:1503\u20131509.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cgh.2006.01.014","volume":"4","author":"S. Rodriguez-Stanley","year":"2006","unstructured":"Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al.: Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006, 4:442\u2013450.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"56_CR29","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1023\/A:1026645914933","volume":"44","author":"C. Prakash","year":"1999","unstructured":"Prakash C, Clouse RE: Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999, 44:2373\u20132379.","journal-title":"Dig Dis Sci"},{"key":"56_CR30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1067\/mhj.2000.108514","volume":"140","author":"I. Varia","year":"2000","unstructured":"Varia I, Logue E, O\u2019Connor C, et al.: Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000, 140:367\u2013372.","journal-title":"Am Heart J"},{"key":"56_CR31","first-page":"G460","volume":"275","author":"A.B. Gorelick","year":"1998","unstructured":"Gorelick AB, Koshy SS, Hooper FG, et al.: Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998, 275:G460\u2013G466.","journal-title":"Am J Physiol"},{"key":"56_CR32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gut.42.6.807","volume":"42","author":"P.L. Peghini","year":"1998","unstructured":"Peghini PL, Katz PO, Castell DO: Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998, 42:807\u2013813.","journal-title":"Gut"},{"key":"56_CR33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2036.2006.02772.x","volume":"23","author":"D. Broekaert","year":"2006","unstructured":"Broekaert D, Fischler B, Sifrim D, et al.: Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006, 23:365\u2013370.","journal-title":"Aliment Pharmacol Ther"},{"key":"56_CR34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/gut.2003.025460","volume":"53","author":"J. Arts","year":"2004","unstructured":"Arts J, Tack J, Galmiche JP: Endoscopic antireflux therapies. Gut 2004, 53:1207\u20131214.","journal-title":"Gut"},{"key":"56_CR35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10620-005-1610-4","volume":"50","author":"J. Arts","year":"2005","unstructured":"Arts J, Lerut T, Rutgeerts P, et al.: A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Dig Dis Sci 2005, 50:351\u2013356.","journal-title":"Dig Dis Sci"},{"key":"56_CR36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1091-255X(99)80071-7","volume":"3","author":"G.M. Campos","year":"1999","unstructured":"Campos GM, Peters JH, DeMeester TR, et al.: Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999, 3:292\u2013300.","journal-title":"J Gastrointest Surg"},{"key":"56_CR37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cgh.2006.01.011","volume":"4","author":"J. Swoger","year":"2006","unstructured":"Swoger J, Ponsky J, Hicks DM, et al.: Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006, 4:433\u2013441.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-007-0056-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0056-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:36Z","timestamp":1559436996000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-007-0056-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s11938-007-0056-5","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}